A pilot study of gene and expression in hepatocellular carcinoma patients.

Clicks: 218
ID: 73315
2019
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
gene and (YAP (play a pivotal role in organ size control and tumorigenesis.In the present pilot study, we investigate the expression of Livin gene and YAP1 in hepatitis C virus (HCV) associated hepatocellular carcinoma (HCC) compared to other HCV patients and controls.Methods: the studied patients were divided into three groups 30 patients in each group in addition to 30 healthy subjects as a control group. Relative quantification of gene and YAP-1 were assessed by quantitative Real Time RT-PCR (qPCR) in all studied patients and healthy controls. other laboratory investigations were done including complete blood count (CBC),international normalized ratio (INR) as well as liver function tests and tumor markers.Significant overexpression of gene and YAP-1 was detected in HCC group followed by Hepatitis C Virus (HCV) untreated group then HCV treated group. The relative quantitation (RQ) of both genes showed positive correlation to the carcinoembryonic antigen (CEA) level and a significant relation was found between higher level of and genes and tumor size. The overall survival rate was low in those patients with high levels of and genes so they were considered as indicators of a bad prognosis.There is overexpression of gene and in hepatocellular carcinoma patients. They can be used as indicators of bad prognosis of the disease pathway together with low survival rate.
Reference Key
badr2019aheliyon Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Badr, Eman Ae;El Tantawy El Sayed, Ibrahim;Assar, Mohamed Fa;Ali, Sahar Am;Ibrahim, Nehal S;
Journal Heliyon
Year 2019
DOI 10.1016/j.heliyon.2019.e02798
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.